Incannex Healthcare Inc. Description Of Growth Rate Used To Extrapolate Cash Flow Projections
Incannex Healthcare Inc. (IXHL) had Description Of Growth Rate Used To Extrapolate Cash Flow Projections of 11.20% as of 2023-06-30, per its 20-F filed 2023-10-31.
Discontinued › Notes
ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections · last filed 2023-10-31
- 2023-06-30: Description Of Growth Rate Used To Extrapolate Cash Flow Projections 11.20%.
| Period end | Description Of Growth Rate Used To Extrapolate Cash Flow Projections |
|---|---|
| 2023-06-30 | 11.20% 20-F · filed 2023-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |